Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Feb 24, 2023 4:16pm
81 Views
Post# 35304396

RE:RE:Highs, Trends and Nonsense

RE:RE:Highs, Trends and NonsensePoof, we all know that Bioasis has earned its 1.5 cent share price. We know about debt.

Rathjen essentially removed xB3 from the picture for the last 12 or 15 months, creating complete confusion for a market trying to figure out what Bioasis is worth.

She entered a deals that are almost worthless.

She replaced xB3 with Cresence EGF as the major Bioasis program.

Midatech, through Ladenburg Thalmann (LT), could have had the Cresence stuff if it wanted. The Cresence deal Bioasis was months after LT became involved with Bioasis. I think that the Cresence deal was meant to diminish the value of xB3, to sow doubt about xB3, and I think it succeeded in that.

Rathjen put xB3-001 on the shelf and yet she accidently leaked a deal with Ellipses for it, a deal that she likely had to cancel because of the disclosure problem it would have caused if it went through after the leak and after the "merger."

Has there been a "stand still" for the last 12 or 15 months? Is there Hunter data that could be disclosed? Have there been deals available that have been precented from getting done?

And she has caused, or has been unable to prevent, the share price from dropping over 95% since the day she became CEO. Talking about trends, it's almost impossible to create a worse trend.

This stuff is either a setup or it was caused by incompetence. Either makes the case for her immediate removal from Bioasis.

Again, poof, why are you pumping this nonsense?

jd
<< Previous
Bullboard Posts
Next >>